Bifogade filer
PDF
Kurs
+3,18%
Likviditet
81,2 MSEK
Kalender
| Tid* | ||
| 2025-10-22 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-30 | N/A | X-dag ordinarie utdelning ARJO B 0.95 SEK |
| 2025-04-29 | N/A | Årsstämma |
| 2025-04-29 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-17 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-19 | - | X-dag ordinarie utdelning ARJO B 0.90 SEK |
| 2024-04-18 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-30 | - | Bokslutskommuniké 2023 |
| 2023-10-19 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-07-12 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-21 | - | X-dag ordinarie utdelning ARJO B 0.85 SEK |
| 2023-04-20 | - | Årsstämma |
| 2023-04-20 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-25 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-25 | - | X-dag ordinarie utdelning ARJO B 1.15 SEK |
| 2022-04-22 | - | Årsstämma |
| 2022-04-22 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-28 | - | X-dag ordinarie utdelning ARJO B 0.85 SEK |
| 2021-04-27 | - | Årsstämma |
| 2021-04-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-10-28 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-30 | - | X-dag ordinarie utdelning ARJO B 0.65 SEK |
| 2020-06-29 | - | Årsstämma |
| 2020-04-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-10-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning ARJO B 0.55 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-04 | - | Bokslutskommuniké 2018 |
| 2018-10-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | X-dag ordinarie utdelning ARJO B 0.50 SEK |
| 2018-05-04 | - | Årsstämma |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-29 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President & CEO of Arjo, a role he has held since 2017. Niclas Sjöswärd, currently CFO of Arjo, has been appointed interim President & CEO. The process of recruiting a new CEO will be initiated immediately.
The Board of Directors would like to thank Joacim for the period of close to eight years that we have had the opportunity to work together. Arjo has since its spinoff developed into a company with a solid foundation under Joacim's leadership. However, work remains to further develop the company to its full potential and the Board of Directors believe that now is a good time for a new CEO to step in and lead Arjo going forward.
Due to the above, the Capital Markets Update planned for January 30th in Stockholm, Sweden, has been postponed. Arjo will present the year-end report 2024 and 2025 outlook at a teleconference on January 30th. More information on this will be communicated separately.
For more information, please contact:
Johan Malmquist, Chairman of the Board
Maria Nilsson, EVP Communications & Public Relations
+46 734 244 515
maria.nilsson@arjo.com
This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CET on January 14, 2025.
About Arjo
At Arjo, we are convinced that good conditions for mobility in healthcare environments are a central part of offering high-quality care. Our products and solutions for patient transfer, hygiene, disinfection, diagnostics, treatment of leg ulcers, prevention of pressure ulcers and venous thrombosis, as well as our healthcare beds, are designed to promote mobility, safety and dignity in all healthcare situations. With over 65 years of experience in improving everyday life for patients and caregivers, and a global team of over 6,500 people, we are constantly working to create better outcomes for people facing mobility challenges. www.arjo.com